Constanza Alcaino

Constanza Alcaino

Auto-generated profile, based on publicly available information

Constanza Alcaino

Institute of Metabolic Science, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CAConstanza Alcaino
Constanza Alcaino
KKKaitlyn R. Knutson
Kaitlyn R. Knutson
ATAnthony J. Treichel
Anthony J. Treichel
GYGulcan Yildiz
Gulcan Yildiz
PSPeter R. Strege
Peter R. Strege
ABArthur Beyder
Arthur Beyder
Significance: Mechanical forces are important for normal gastrointestinal tract function. The enterochromaffin cells in the gastrointestinal epithelium have been proposed, but not previously shown, to be specialized sensors that convert forces into serotonin release, and serotonin released from these cells is important for normal gastrointestinal secretion and motility. The findings in this study show that some enterochromaffin cells are indeed mechanosensitive, and that they use mechanosensitive Piezo2 channels to generate an ionic current that is critical for the intracellular Ca2+increase, serotonin release, and epithelial fluid secretion.

13 December 2022 in The Journal of Physiology
Verified
Journal Article
Closed access
KKKaitlyn R. Knutson
Kaitlyn R. Knutson
SWSara T. Whiteman
Sara T. Whiteman
CAConstanza Alcaino
Constanza Alcaino
AMArnaldo Mercado‐Perez
Arnaldo Mercado‐Perez
IFIsabelle Finholm
Isabelle Finholm
ABArthur Beyder
Arthur Beyder

13 December 2024 in Science Advances
Verified
Journal Article
Open access
Yining XuYining Xu
Yining Xu
CMCécilia Bohns Michalowski
Cécilia Bohns Michalowski
JKJackie Koehler
Jackie Koehler
TDTamana Darwish
Tamana Darwish
NGNunzio Guccio
Nunzio Guccio
AGAna Beloqui García
Ana Beloqui García
Modulating the endogenous stores of gastrointestinal hormones is considered a promising strategy to mimic gut endocrine function, improving metabolic dysfunction. Here, we exploit mouse and human knock-in and knockout intestinal organoids and show that agents used as commercial lipid excipients can activate nutrient-sensitive receptors on enteroendocrine cells (EECs) and, when formulated as lipid nanocarriers, can bestow biological effects through the release of GLP-1, GIP, and PYY from K and L cells. Studies in wild-type, dysglycemic, and gut Gcg knockout mice demonstrated that the effect exerted by lipid nanocarriers could be modulated by varying the excipients (e.g., nature and quantities), the formulation methodology, and their physiochemical properties (e.g., size and composition). This study demonstrates the therapeutic potential of using nanotechnology to modulate release of multiple endogenous hormones from the enteroendocrine system through a patient-friendly, inexpensive, and noninvasive manner.

22 November 2024 in The Journal of Physiology
Verified
Journal Article
Open access
CAConstanza Alcaino
Constanza Alcaino
FRFrank Reimann
Frank Reimann
FGFiona M. Gribble
Fiona M. Gribble
The incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play critical roles in co‐ordinating postprandial metabolism, including modulation of insulin secretion and food intake. They are secreted from enteroendocrine cells in the intestinal epithelium following food ingestion, and act at multiple target sites including pancreatic islets and the brain. With the recent development of agonists targeting GLP‐1 and GIP receptors for the treatment of type 2 diabetes and obesity, and the ongoing development of new incretin‐based drugs with improved efficacy, there is great interest in understanding the physiology and pharmacology of these hormones. image

3 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSimone Mazzaferro
Simone Mazzaferro
HCHsiao-Jou Cortina Chen
Hsiao-Jou Cortina Chen
OCOlivier Cahn
Olivier Cahn
AYAndrian Yang
Andrian Yang
DSDmytro Shepilov
Dmytro Shepilov
FMFlorian Tobias Merkle
Florian Tobias Merkle
Drugs like semaglutide (a.k.a. Ozempic/Wegovy) that activate the glucagon-like peptide-1 receptor (GLP-1R) are a promising therapy for obesity and type 2 diabetes (T2D). Animal studies suggest that these drugs likely function by stimulating GLP-1R on appetite-suppressing neuron populations in the brain, but it is still unclear how they act to reduce food intake in humans. We therefore generated appetite-regulatory hypothalamic neurons from human pluripotent stem cells (hPSCs) to study their responses to GLP-1R agonists by calcium imaging and electrophysiology. We found that hPSC-derived proopiomelanocortin (POMC) and other hypothalamic neuron subtypes expressed GLP1R mRNA, and many of these neurons robustly responded to GLP-1R agonists by membrane depolarization, increased action potential firing, and extracellular calcium influx that persisted long after agonist withdrawal. The observed GLP-1R-induced response was likely mediated by the activation of PKA and L-type calcium channels, and led to significant changes in gene expression. These findings provide mechanistic insight into how GLP-1R agonists may suppress appetite in humans.

23 November 2022 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
CAConstanza Alcaino
Constanza Alcaino